SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors upcoming FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the November 22 target date and the companys amended application emphasizing upper-limb function data. Bullish traders interpret the longer-term data, rare-disease policy discussions and recent commercial hiring as encouraging signs, while skeptics cite prior FDA concerns and say approval remains uncertain.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention for its breakout ahead of the expected Q3 earnings report, with traders focused on BRIUMVIs growth and possible further upside. Buyout and short-squeeze chatter is prominent but speculative; some traders instead attribute the move to earnings expectations and the companys commercial momentum.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could fall after early 2027 has fueled a sharp selloff and concern about future pricing and revenue. Traders disagree over whether the warning signals sustained pressure or is only a preliminary estimate, pointing to CMSs more stable outlook while criticizing CorMedixs lack of clarification.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention after a sharp Nasdaq selloff tied to weakness in technology and semiconductor stocks, with traders debating whether concerns about AI spending and earnings justify more downside or whether the decline is an oversold dip to buy. The late-session rebound prompted some dip-buying optimism, but bearish traders continued to warn that the correction may not be over.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS REGAL Phase 3 leukemia trial reached its prespecified event threshold, triggering final analysis and putting the GPS survival readout in focus. Traders are sharply divided over whether GPS will show a benefit or whether control-arm outcomes and trial assumptions could undermine the bull case, amid volatile trading and speculation about short positioning.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens PAPZIMEOS commercial launch and stronger-than-expected quarterly results, including a move to profitability, are driving bullish discussion about its growth prospects. Traders also debate whether potential INO-3107 competition could challenge PAPZIMEOS and whether heavy short interest is amplifying the stocks moves.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 76,874.98691422 USD and is down -4.82 over the last 24 hours. It is currently trading on 12773 active market(s) with $58,826,736,014.03 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

A reported major Binance security breach and temporary withdrawal suspension have fueled Bitcoin selling and concerns about crypto exchange security. Traders disagree over whether the incident signals broader risk or is isolated to Binance, with some viewing the pullback as a buying opportunity and others warning of further downside.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

ARM is caught in a sharp semiconductor and AI-stock selloff, with traders citing its rich valuation and questioning whether AI demand can support the growth priced in. Some see the drop as an overdone sector-driven correction and are buying the dip, while others expect further downside.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its quarterly report is fueling concern about slowing ad growth, analyst target cuts, and weakness across advertising-related stocks. Traders debate whether the decline reflects deteriorating prospects or has overshot the companys growth and cash-generation fundamentals, with earnings seen as a key test.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

Silvers sharp selloff, amid inflation concerns and expectations of higher interest rates, is driving attention to SLV. Traders are split between calling the decline an oversold buying opportunity and warning that selling may continue, with some blaming market manipulation without evidence.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in ImageneBio, Inc. (NASDAQ:IMA) Increases By 51.7%

ImageneBio, Inc. (NASDAQ:IMA - Get Free Report) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totaling 587,281 shares, a growth of 51.7...

IMA Stock Surges 24%, Breaks 50-DMA For First Time Since February – What's Driving The Rally?

Equity

ImageneBio shares jumped to their highest levels in more than a month after the company announced a $30 million fundraising from institutional investors.

ImageneBio $30 Million Private Placement Ignites Stock

ImageneBio shares rise after a $30 million private placement to advance IMG-007 development for atopic dermatitis and alopecia areata.read more...

ImageneBio (NASDAQ:IMA) Stock Price Down 8.5%  - Here's Why

ImageneBio (NASDAQ:IMA) Shares Down 8.5% - Here's What Happened...

Atlas Venture Life Science Advisors LLC Buys New Position in ImageneBio, Inc. $IMA

Atlas Venture Life Science Advisors LLC bought a new position in shares of ImageneBio, Inc. (NASDAQ:IMA - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F...

Wall Street Zen Upgrades ImageneBio (NASDAQ:IMA) to "Hold"

Wall Street Zen upgraded ImageneBio from a "strong sell" rating to a "hold" rating in a report on Saturday...

BML Capital Management LLC Makes New Investment in ImageneBio, Inc. $IMA

BML Capital Management LLC purchased a new position in ImageneBio, Inc. (NASDAQ:IMA - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities...

ImageneBio (NASDAQ:IMA) Shares Up 2.4% - Still a Buy?

ImageneBio (NASDAQ:IMA) Stock Price Up 2.4% - Still a Buy...

ImageneBio (NASDAQ:IMA) Trading Up 0.5% - Should You Buy?

ImageneBio (NASDAQ:IMA) Shares Up 0.5% - Here's Why...

Insider Buying: ImageneBio (NASDAQ:IMA) Director Acquires 16,000 Shares of Stock

ImageneBio, Inc. (NASDAQ:IMA - Get Free Report) Director Joseph Slattery acquired 16,000 shares of the company's stock in a transaction on Wednesday, December 24th. The shares were bought at an...

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. It focuses on the development of new medicines with differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The company was founded in February 2016, and is headquartered in San Diego, CA.

ImageneBio Inc.

Neutral Sentiment

<ul class="summary-bullets"><li>ImageneBio said it plans to use the proceeds to support the development of IMG-007 for alopecia areata and late-stage work in atopic dermatitis.</li><li>The biotech firm is currently conducting its Phase 2b ADAPTIVE trial for IMG-007, with topline results expected in 2027.</li><li>ImageneBio will present the latest data from the study at the Annual Society for Investigative Dermatology Meeting in May.</li></ul>Shares of ImageneBio, Inc. (IMA) surged more than 24% on Monday, crossing their 50-day moving average (50-DMA) for the first time since Feb. 27, 2026, after the biotech firm announced fresh funding from institutional investors in the form of a $30 million private placement.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://in.tradingview.com/chart/teA7VKVN/?symbol=NASDAQ%3AIMA"><img src="https://news.stocktwits-cdn.com/IMA_jpg_91814193cc.webp" alt="IMA.jpg"></a>Source: TradingViewImageneBio said it plans to use the proceeds to support the development of IMG-007 for alopecia areata and late-stage work in atopic dermatitis. The deal involves the sale of pre-funded warrants to purchase over 5.7 million shares at $5.199 per share.The financing round is led by new investor Coastlands Capital, with participation from Trails Edge Capital Partners and existing backers Omega Funds and OrbiMed.<h2 class="st-heading-2">What’s The Latest On Drug To Treat Dermatitis?</h2>ImageneBio is currently conducting a Phase 2b ADAPTIVE trial for IMG-007, with topline results expected in 2027. The study, which began enrollment in mid-2025 across North America, continues to show a favorable safety and tolerability profile, as indicated by a recent blinded review. A Blinded review means the people running a clinical trial do not know which patients are receiving the treatment.IMG-007 has been well tolerated across studies involving more than 150 patients, with no serious safety concerns reported. Reported side effects have been minimal, with very low rates of mild injection-site reactions.The company has also recently submitted a protocol update to expand dosing strategies and explore more patient-friendly treatment schedules. ImageneBio will present the latest data from the study at the Annual Society for Investigative Dermatology Meeting in May.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/IMA">IMA</a> on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.One bullish user said buying the stock was a “no-brainer,” comparing the company’s market cap to the funding amount.<stembedurl>https://stocktwits.com/Jimmytrader35/message/650097652</stembedurl>Another user expects the stock to climb all week.<stembedurl>https://stocktwits.com/Jimmytrader35/message/650131942</stembedurl>Year-to-date, the stock has gained around 5%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/cag-stock-crashes-to-near-17-year-lows/cZJ85DBRIun">CAG Stock Crashes To Near 17-Year Lows, But Retail Sees ‘Buying Opportunity Of A Decade’</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

ImageneBio, Inc.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$4.10
Prev Close	$4.05
Open	$4.05
Dividend Yield	0.00%
50-Day Moving Average	$4.70
Beta	0.88
Avg. Volume	16,606.29
PE Ratio	-0.78

52-Week High	$8.84
52-Week Low	$3.88
Market Capitalization	$45.97M
EPS (Annual)	-$9.64
Price to Book	0.32
Revenue Per Employee	$53,333.33

Feed

News

Sentiment

Earnings

Fundamentals

Info

IMA Fundamentals